^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Predictive biomarkers of response to anti-PD-1 treatment in non-small cell lung cancer patients.

Excerpt:
NSCLC patients treated with nivolumab or pembrolizumab were studied….Early changes in serum TNF-a levels and high serum TNF-a levels at early stage in non-small cell lung cancer patients correlate to response to anti-PD-1 treatment.
DOI:
10.1200/JCO.2018.36.15_suppl.e21076